Compare Abbott Laboratories (ABT) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Vanguard Real Estate Index Fund ETF — how do they compare? Abbott Laboratories trades at $111.86 (market cap $191.92B), while Vanguard Real Estate Index Fund ETF trades at $98.15. The key difference: Abbott Laboratories pays a 2.27% dividend while Vanguard Real Estate Index Fund ETF pays none, and Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | VNQ | |
|---|---|---|
Market Cap | $191.92B | — |
Sector | Health | — |
52-Week High | $136.62 | $100.95 |
52-Week Low | $82.57 | $87.00 |
Enterprise Value | $218.92B | — |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.02% with strong analyst support (75.6% buy ratings) and a $120.70 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026. Fundamentals remain solid with $44.33B revenue, 11.65% net margin, and improving cash flow trends. Recent CE Mark approval for Libre Duo glucose-ketone sensors highlights innovation momentum.
ABT presents a compelling investment case with strong fundamentals, positive analyst sentiment, and innovative product pipeline. Key risks include competitive pressures in medical devices and potential macroeconomic headwinds affecting healthcare spending. The stock's current valuation at 35.15 P/E appears reasonable given growth prospects and dividend stability.
VNQ, the Vanguard Real Estate ETF, trades at $97.31, up 0.21% on the day, but technical indicators signal a bearish trend with moving averages and overall signals pointing lower. The ETF's financial ratios are not disclosed in the provided data, limiting fundamental assessment. Recent news highlights institutional selling, with firms like City Holding Co. and Bank of America reducing positions, while media comparisons focus on VNQ's U.S. REIT exposure and low fees versus global alternatives.
Outlook remains cautious due to bearish technicals and institutional outflows, though the neutral oscillator reading and upcoming dividend in June 2026 offer some balance. Risks include interest rate sensitivity and real estate market volatility, but the ETF's low expense ratio and diversification provide a defensive income option for long-term investors amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
